Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers-Reference-Cited by-同舟云学术

Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA-Mutant Cancers

Published:2020-11-04 Issue:2 Volume:27 Page:447-459
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Jhaveri Komal,Chang Matthew T.,Juric Dejan,Saura Cristina^ORCID,Gambardella Valentina,Melnyk Anton,Patel Manish R.,Ribrag Vincent,Ma Cynthia X.,Aljumaily Raid,Bedard Philippe L.^ORCID,Sachdev Jasgit C.^ORCID,Dunn Lara,Won Helen^ORCID,Bond John,Jones Surai,Savage Heidi M.,Scaltriti Maurizio^ORCID,Wilson Timothy R.,Wei Michael C.,Hyman David M.

Funder

Memorial Sloan-Kettering Cancer Center

F. Hoffmann-La Roche Ltd.Memorial Sloan-Kettering Cancer CenterMemorial Sloan-Kettering Cancer Center

NIH

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

2. Molecular pathways and targeted therapies in head and neck cancers pathogenesis;Frontiers in Oncology;2024-06-17

3. Phase Ib dose-escalation trial of taselisib (GDC-0032) in combination with HER2-directed therapies in patients with advanced HER2+ breast cancer;ESMO Open;2024-06

4. What Do German Molecular Tumor Boards Recommend in Patients with PIK3CA-Mutated Tumors? Launch and First Results from the German Transsectoral Molecular Tumor Board Exchange Platform Deutschland;Oncology Research and Treatment;2024-05-07

5. Isolation of proteins on chromatin (iPOC) reveals signaling pathway-dependent alterations in the DNA-bound proteome;2024-04-10